A Phase 1 interventional study of HWK-016, MUCIN-16-targeted ADC and Bevacizumab in PROC, Platinum Resistant Ovarian Cancer and Endometrial Cancer, sponsored by Whitehawk Therapeutics, Inc.. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Whitehawk Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 715 studies in Endometrial Neoplasms with a site in United States — 196 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.
Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 106th largest by planned enrollment of the 591 interventional ones that give a count, is one of 46 that started in 2026, is one of 192 in phase 1, reaches primary completion later than 172 of the 283 other live ones, and was the 686th registered.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →196 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Oklahoma · Sites in United States
Ages 18+ · Women only
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Sutro Biopharma, Inc. · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 2 more countries
Ages 18+ · Women only
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 355 Endometrial Neoplasms studies recruiting now, 265 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
715 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 277 · Phase 2 264 · Phase 3 40 · Phase 4 3
First in 1987; this study’s year is marked. 46 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 265 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 60 across the 591 interventional studies, 148 across the 100 observational. Of the 386 that completed or were terminated, 132 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 715 have an industry lead sponsor. The 10 most frequent:
Whitehawk Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Whitehawk Therapeutics, Inc. has 2 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
97 of the studies in Endometrial Neoplasms with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04634877Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | 2026-11-20 |
| NCT03785288Phase 3Kara Romano, MDVaginal Cuff Brachytherapy Fractionation Study | 2027-01-30 |
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT05256225Phase 3National Cancer Institute (NCI)Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | 2027-10-31 |
Add all 97 to your calendar (.ics) → With an account.
Among the 715 studies in Endometrial Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group.
The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.
HWK-016-101 is a Phase 1 study evaluating HWK-016, a mucin-16 (MUC-16) targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have one of the following solid tumor cancers:
Monotherapy escalation, backfill and expansion cohorts:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating doses of HWK-016, a MUCIN-16-targeted ADC administered intravenously (IV)
Drug: HWK-016, MUCIN-16-targeted ADC
Dose Optimization of Recommended dose for expansion 1
Drug: HWK-016, MUCIN-16-targeted ADC
Expanded enrolment at Recommended Dose for Expansion 2 in Ovarian Cancer
Drug: HWK-016, MUCIN-16-targeted ADC
Expansion of enrolment at RDE 1 or 2 in Tumor TBD
Drug: HWK-016, MUCIN-16-targeted ADC
Escalating doses of HWK-016, a MUCIN-16-targeted ADC administered intravenously (IV) combined with Bevacizumab (IV) in Ovarian cancer
Drug: HWK-016, MUCIN-16-targeted ADC · Drug: Bevacizumab
Expansion of enrolment at RDE 1 or 2 in Tumor TBD
Drug: HWK-016, MUCIN-16-targeted ADC
Expanded enrolment at RDE of HWK-016, a MUCIN-16-targeted ADC administered intravenously (IV) combined with Bevacizumab (IV) in Ovarian cancer
Drug: HWK-016, MUCIN-16-targeted ADC · Drug: Bevacizumab
Expanded enrolment at RDE of HWK-016, a MUCIN-16-targeted ADC administered intravenously (IV) combined with Bevacizumab (IV) in Tumor TBD
Drug: HWK-016, MUCIN-16-targeted ADC · Drug: Bevacizumab
HWK-016 is a MUCIN-16-targeted Antibody-Drug-Conjugate (ADC) being developed for the treatment of solid tumors.
Also known as: HWK-016
Bevacizumab administered according to the USPI in 21-day cycles
Determine Maximum Tolerated Dose (MTD)
Determine the highest dose of HWK-016 that can be administered without signs of toxicity, measured at the end of Cycle 1(21-day cycle) by: Incidence and severity of Adverse Events (AE). Incidence of Dose-Limiting Toxicities (DLT). Incidence of Serious Adverse Events (SAE). Evaluate the safety and tolerability of HWK-016 at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer
Time frame: From Cycle 1, Day 1 Until Cycle 1, Day 21 (21-day cycles)
Determine Maximum Administered Dose (MAD)
Determine the highest dose of HWK-016 administered during the dose escalation part of the study, measured at the end of Cycle 1 (21-day cycle) by: Incidence and severity of Adverse Events (AE). Incidence of Dose-Limiting Toxicities (DLT). Incidence of Serious Adverse Events (SAE). Evaluate the safety and tolerability of HWK-016 at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer
Time frame: From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles) until the MTD is reached.
Determine Recommended Dose For Expansion (RDE)
Determine the dose of HWK-016 that will be recommended for further study within the tumor types studied in this clinical trial, measured at the end of Cycle 1, Day 21 (21-day cycle) by: Incidence and severity of Adverse Events (AE). Incidence of Dose-Limiting Toxicities (DLT). Incidence of Serious Adverse Events (SAE). Evaluate the safety and tolerability of HWK-016 at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer.
Time frame: From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycle) until MTD is identified.
Characterize the Volume of Distribution (Vd) of HWK-016 (ADC, total antibody, CPT116, and CPT119)
Pharmacokinetic analysis of HWK-016 in human subjects
Time frame: Cycle 1 and Cycle 4 (21-day cycles)
Maximum Concentration - Cmax of HWK-016 (ADC, total antibody, CPT116, and CPT119)
Maximum amount of study drug and drug components in blood following infusion.
Time frame: At Cycle 1 and Cycle 4 - (21-day cycles)
Time to Maximum Concentration (Tmax) of HWK-016 (ADC, total antibody, CPT116, and CPT119)
Time to reach maximum concentration of drug and drug components in blood following infusion.
Time frame: Cycle 1 and Cycle 4 - (21-day cycles)
Area Under the Concentration Time Curve (AUC) for HWK-016 (ADC, total antibody, CPT116, and CPT119)
The total area under the concentration time curve of study drug and drug components following infusion
Time frame: Cycle 1 and Cycle 4 - (21-day cycles
T1/2 - Half-life of HWK-016 (ADC, total antibody, CPT116, and CPT119)
Time for 1/2 of the infused drug to be eliminated/metabolized
Time frame: Cycle 1 and Cycle 4 - (21-day cycles)
Clearance (CL)
Measured rate at which HWK-016 is cleared from the blood following infusion.
Time frame: Cycle 1 and Cycle 4 (21-day cycles)
Assess ADA (Anti drug antibody) against HWK-016
Using a blood test, determine the risk of developing anti-drug antibodies against HWK-016 following infusion in human patients.
Time frame: Every cycle from Cycle 1, Day 1 (21-day cycles) until 30 days past the last dose of study drug for up to 24 months.
Evaluate the Overall Response Rate (ORR
Measure the response rate to the study drug by CT-scans evaluated using RECIST1.1. Evaluate preliminary antitumor activity of HWK-016 at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer by RECIST Version 1.1
Time frame: From Cycle 1, Day 1 (21-day cycles), every 6-weeks for the first 4 assessments and then every 6 weeks for up to 24 months until disease progression or 24 months, whichever comes first.
Evaluate Overall Survival (OS).
Measure how long a patient lives following treatment with HWK-016. Evaluate the Overall Survival at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer
Time frame: From Cycle 1, Day 1 (21-day cycles) until death or 24 months, whichever comes first.
Evaluate the Duration of Response (DoR) to HWK-016
Measure the time from evidence of response by CT-scan until evidence of progression of cancer. Evaluate the Duration of Response at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer
Time frame: From Cycle 1, Day 1 (21-day cycles) until disease progression or 24 months, whichever comes first.
Evaluate Progression-free Survival (PFS)
Measure the time from the first infusion of HWK-007 until evidence of cancer progression is detected. Evaluate the Progression Free Survival at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer
Time frame: From Cycle 1, Day 1 (21-day cycles) infusion to End of Study (up to 24 months)
Evaluate Disease control Rate (DCR)
Measure the time from Cycle 1, Day 1 that cancer does not worsen by RECIST1.1 criteria. Evaluate the Disease Control Rate at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer
Time frame: From Cycle 1, Day 1 (21-day cycles) infusion to End of Study (up to 24 months
Time to Response (TTR)
Time from Cycle 1, Day 1 infusion of HWK-016 until evidence of response via CT scan according to RECIST1.1 criteria. Evaluate the Time to Response at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer
Time frame: From Cycle 1, Day 1 (21-day cycles) until End of Study or 24 months, whichever comes first
Plan to share: Yes
Supporting information: Clinical study report
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Feb 2028, 23 months after the start.
Of 88 industry-sponsored phase 1 interventional studies under Endometrial Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 69. This study's planned 23 months is below that.
Counting every sponsor, half of 131 studies reached it within 61 months; a quarter within 46 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Whitehawk Therapeutics, Inc.